证券代码：603077 证券简称：和邦生物 公告编号：2025-036 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 重要内容提示： 评级机构中证鹏元在对公司运营环境、经营竞争状况、财务等方面进行综合 分析与评估的基础上，出具了《四川和邦生物科技股份有限公司相关债券 2025 年跟踪评级报告》（以下简称"《评级报告》"），《评级报告》维持公司主体信用等 级为"AA"，维持评级展望为"稳定"；维持"和邦转债"的信用等级为"AA"。 本次评级结果较前次没有变化。 《评级报告》内容详见公司于同日在上海证券交易所网站（www.sse.com.cn） 披露的《四川和邦生物科技股份有限公司相关债券 2025 年跟踪评级报告》。 特此公告。 四川和邦生物科技股份有限公司董事会 前次评级结果：主体信用等级为"AA"，评级展望为"稳定"；"和邦转债" 的信用等级为"AA"。 本次跟踪评级结果：主体信用等级为"AA"，评级展望为"稳定"；"和邦 转债"的信用等级为"AA"。 根据《上市公司证券发行注册管理办法》《上海证券交易所公司债券上市规 则》等相关规定，四川和邦生物科技股份有限公司（以下简称"公司 ...

四川和邦生物科技股份有限公司 相关债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【1232】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未 ...

Group 1 - The chemical sector continues to rise, with the Chemical ETF (516020) showing a maximum intraday increase of 1.83% and closing up 1.53% [1] - Notable stocks in the sector include lithium battery, soda ash, and fluorine chemical companies, with significant gains from Hebang Biological (up 4.76%) and Tianci Materials (up 4.03%) [1] - The chemical sector has attracted significant capital, with a net inflow of 26.418 billion yuan over the past five days, ranking second among 30 sectors [1][3] Group 2 - The "anti-involution" policy is benefiting the lithium battery sector, as it leads to project delays and a healthier supply-demand balance [3] - The chemical industry is currently at the bottom of the cycle, facing challenges from increased competition, but supply-side reforms are expected to optimize the industry structure [4] - The current valuation of the Chemical ETF (516020) is at a low point, suggesting a good opportunity for long-term investment [4] Group 3 - The chemical sector is expected to undergo a re-pricing based on cost factors, focusing on green and low-carbon initiatives [5] - Domestic policies frequently emphasize supply-side requirements, while international uncertainties in chemical supply are increasing [5] - The Chemical ETF (516020) provides a diversified investment opportunity across various sub-sectors, with a significant portion allocated to large-cap leading stocks [6]

Group 1 - The Low-E glass concept increased by 3.12%, ranking 8th among concept sectors, with 11 stocks rising, including Hainan Development hitting the daily limit, and Qibin Group, Hebang Biology, and Yaopi Glass showing gains of 5.01%, 4.76%, and 4.34% respectively [1][2] - The Low-E glass sector saw a net inflow of 376 million yuan, with 7 stocks receiving net inflows, and 6 stocks exceeding 10 million yuan in net inflow, led by Hainan Development with 204 million yuan [2][3] - The net inflow ratios for Hainan Development, Qibin Group, and Hebang Biology were 16.32%, 14.61%, and 14.35% respectively, indicating strong investor interest [3] Group 2 - The top stocks in the Low-E glass sector based on net inflow included Hainan Development, Hebang Biology, Qibin Group, and Nanbo A, with respective net inflows of 2038.49 million yuan, 715.68 million yuan, 633.98 million yuan, and 238.91 million yuan [3][4] - The trading volume and turnover rates for these stocks were notable, with Hainan Development showing a turnover rate of 13.86% and a daily increase of 10.01% [3]

截止 2025 年 7 月 24 日，本员工持股计划所持有的公司股票已经通过集中竞 一、本员工持股计划的基本情况 公司于 2024 年 1 月 24 日召开第六届董事会第十一次会议，并于 2024 年 2 月 19 日召开 2024 年第一次临时股东大会，均审议通过了《<四川和邦生物科技 股份有限公司第三期员工持股计划（草案）>及其摘要的议案》，具体内容详见公 司在上海证券交易所网站（http://www.sse.com.cn）及指定媒体披露的相关公 告。 2024 年 4 月 25 日，公司收到中国证券登记结算有限责任公司出具的《过户 登记确认书》，确认公司回购专用证券账户所持有的 106,086,829 股公司股票已 于 2024 年 4 月 24 日通过非交易过户至四川和邦生物科技股份有限公司-第三期 员工持股计划账户，公司第三期员工持股计划的锁定期为 12 个月，自公司公告 最后一笔标的股票过户至员工持股计划名下之日起计算，具体内容详见公司在上 海证券交易所网站（http://www.sse.com.cn）及指定媒体披露的相关公告。 二、本员工持股计划股票出售情况及后续安排 证券代码：603077 证 ...

Group 1 - The chemical sector continues to rise, with the chemical ETF (516020) showing a significant opening increase before stabilizing, currently up by 0.3% [1][2] - Key stocks in the sector include Yipuli, which hit the daily limit, and other companies like Hebang Bio and Hongda shares, which rose over 2% and 1% respectively [1][2] - Recent inflows into the chemical ETF indicate strong market interest, with a net subscription of 122 million yuan on July 22 and a total of 146 million yuan over the past five trading days [1][2] Group 2 - The overall profit level in China's chemical industry is currently low, prompting many companies to seek improvements in the competitive landscape, necessitating a new round of supply-side reforms [4] - The supply growth rate in the chemical sector has significantly declined, with institutional holdings at a low point, enhancing market expectations for supply-side reforms [5] - The chemical industry is expected to enter a new long-term prosperity cycle, driven by recent policy changes aimed at boosting economic confidence and improving supply-side conditions [6] Group 3 - The chemical ETF (516020) is currently at a low valuation point, with a price-to-book ratio of 2.08, indicating a favorable time for long-term investment [5] - The potential for industry-wide production cuts and environmental regulations could lead to a significant impact on supply-demand dynamics, particularly for high-concentration chemical products [6]

Investment Rating - The report maintains an "Outperform" rating for the basic chemical industry [2] Core Viewpoints - The basic chemical sector has outperformed the market, with the industry index rising by 1.8% from July 11 to July 18, compared to a 0.7% increase in the Shanghai Composite Index [9][20] - The report highlights significant price increases in TDI, glyphosate, and glufosinate due to supply disruptions and rising demand, particularly in South America [6][31][33] Summary by Sections 1. Core Viewpoints - The basic chemical sector is expected to benefit from supply-side reforms and improved demand due to recent government policies aimed at stabilizing the economy [17] - The report emphasizes the potential for long-term investment in core assets as the profitability of chemical products has likely bottomed out, suggesting a recovery in valuations [17][18] 2. Overall Performance of the Chemical Sector - The basic chemical industry index has shown a year-to-date increase of 10.8%, outperforming both the Shanghai Composite and ChiNext indices by 5.4% and 4.5%, respectively [20][26] 3. Individual Stock Performance in the Chemical Sector - Among 424 stocks in the basic chemical sector, 251 stocks rose while 162 fell during the reporting week, with notable gainers including Shangwei New Materials (+148.8%) and Dongcai Technology (+33.2%) [29][30] 4. Key News and Company Announcements - A fire at Covestro's TDI plant in Germany has led to significant supply disruptions, creating opportunities for price increases in TDI [31][32] - Glyphosate prices have increased to 25,500 CNY per ton, reflecting a 7.16% month-over-month rise, driven by reduced inventory levels [33] - New regulations on glufosinate are expected to constrain supply, potentially leading to price increases as the market adjusts [34]

Core Viewpoint - The Low-E glass concept sector experienced a decline of 0.89%, ranking among the top losers in the market, with significant drops in stocks such as Yamaton and Jinjing Technology [1][2]. Group 1: Market Performance - As of July 18, the Low-E glass concept sector saw a notable decrease, with Yamaton hitting the daily limit down, while other companies like Jinjing Technology and Yaopi Glass also faced substantial declines [1]. - In contrast, four stocks within the sector recorded gains, with Hainan Development leading at an increase of 3.12% [1]. Group 2: Capital Flow - The Low-E glass concept sector experienced a net outflow of 72 million yuan, with eight stocks seeing capital outflows, primarily Yamaton, which had a net outflow of 55.16 million yuan [2]. - Other companies with significant capital outflows included Jinjing Technology and Yaopi Glass, with net outflows of 36.39 million yuan and 12.98 million yuan, respectively [2]. - Conversely, Hainan Development, Beibo Shares, and Hebang Biological were among the stocks with the highest net inflows, attracting 49.97 million yuan, 5.45 million yuan, and 1.49 million yuan, respectively [2].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、获得补助的基本情况 2025 年 7 月 18 日，四川和邦生物科技股份有限公司（以下简称"公司"） 收到与收益相关的政府补助 300 万元、公司全资子公司乐山和邦农业科技有限公 司收到与收益相关的政府补助 1,000 万元，合计金额 1,300 万元，占公司 2024 年度经审计的归属于上市公司股东净利润的 41.32%。 | 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-034 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 四川和邦生物科技股份有限公司 关于获得政府补助的公告 根据《企业会计准则第 16 号—政府补助》等相关规定，本次政府补助属于 与收益相关的政府补助，将对公司 2025 年度的利润产生积极影响，具体会计处 理及对公司损益的影响最终以会计师年度审计确认后的结果为准，敬请广大投资 者注意投资风险。 特此公告。 四川和邦生物科技股份有限公司董事会 2025 年 7 月 19 日 ...

Core Viewpoint - The company and its wholly-owned subsidiary received a total government subsidy of 13 million yuan, which will positively impact the company's profits for the fiscal year 2025 [1] Group 1: Government Subsidy Details - The company received a subsidy of 3 million yuan, while its subsidiary, Leshan Hebang Agricultural Technology Co., Ltd., received 10 million yuan [1] - The total subsidy represents 41.32% of the company's audited net profit attributable to shareholders for the fiscal year 2024 [1] - The subsidy is classified as a government grant related to income, indicating a direct positive effect on the company's financial performance [1] Group 2: Financial Impact - The subsidy is expected to have a favorable impact on the company's profit for the fiscal year 2025 [1] - The specific accounting treatment and the exact impact on the company's financial results will be confirmed after the annual audit by the accountant [1]